Full Text
Comparing ITC Results From Lenvatinib Plus Everolimus For Second-Line Treatment of Advanced/Metastatic Renal Cell Carcinoma- Crossover Versus No Crossover

Abstract

Authors

G Tremblay SA Garib G Meir HJ McElroy M Guo

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×